| Issue Date | Title | Involved Person(s) |
| 2016 | Molecular recognition of the catalytic zinc(II) ion in MMP-13 : structure-based evolution of an allosteric inhibitor to dual binding mode inhibitors with improved lipophilic ligand efficiencies | Fischer, Thomas; Riedl, Rainer |
| 24-Oct-2015 | Emodin, eine mutmaßlich anti-diabetisch wirksame Verbindung, beeinträchtigt die Glukosetoleranz adipöser Mäuse | Abu Eud, Sameer; Adams, Michael; Scherer, Thomas; Torres-Gomez, Hector; Riedl, Rainer; Luger, Anton; Fürnsinn, Clemens |
| 25-Feb-2015 | Cover Picture: Merging allosteric and active site binding motifs : de novo generation of target selectivity and potency via natural‐product‐derived fragments (ChemMedChem 3/2015) | Lanz, Jan; Riedl, Rainer |
| 2015 | Merging allosteric and active site binding motifs : de novo generation of target selectivity and potency via natural-product-derived fragments | Lanz, Jan; Riedl, Rainer |
| 2014 | Fighting the resistance | Riedl, Rainer |
| 2014 | Nicht nur Metalloproteasen im Visier | Riedl, Rainer |
| 25-Sep-2013 | Tackling antibiotic resistance | Riedl, Rainer |
| Jan-2013 | Drug discovery through a chemist’s eyes | Riedl, Rainer |
| Jan-2013 | Organic chemistry : the heart and soul of drug discovery | Riedl, Rainer |
| 2013 | Bridging the disciplines : cancer diagnostics & treatment | Riedl, Rainer |
| 2012 | Synthese und medizinalchemische Optimierung von Tetrazyklinanaloga | Riedl, Rainer; Brand, Michael |
| Jun-2011 | Drug discovery in the academic setting | Riedl, Rainer |
| 16-Sep-2010 | Fragment based scaffold hopping in drug discovery | Riedl, Rainer; Fischer, Thomas |
| 2010 | Structure based drug design | Riedl, Rainer |
| 1997 | Fluorescence reporters for phosphodiesterase activity | Berkessel, Albrecht; Riedl, Rainer |
